

## **Abbreviations for Systematic Evidence Review: Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention**

AFF	Atypical femoral fracture
AFib	Atrial fibrillation
AHRQ	Agency for Healthcare Research and Quality
ALN	Alendronate
ARR	Absolute percentage risk reduction
BMD	Bone mineral density
BP	Bisphosphonate
CCT	Controlled clinical trial
CF	Clinical fracture
CI	Confidence intervals
CORE	Continuing Outcomes Relevant to Evista
CVF	Clinical vertebral fracture
DXA	Dual-energy x-ray absorptiometry
E/P	Estrogen/progestin
EPC	Evidence-based Practice Center
FDA	U.S. Food and Drug Administration
FIT	Fracture Intervention Trial
FLEX	Fracture Intervention Trial Long-Term Extension
FN	Femoral neck
FRAX	World Health Organization Fracture Risk Assessment Tool
Fx	Fracture
HORIZON	Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Trial
HR	Hazard ratio
KQ	Key question
LS	Lumbar spine
MOF	Major osteoporotic fracture (hip, clinical vertebral, wrist, proximal humerus)
MORE	Multiple Outcomes of Raloxifene Evaluation
NG	Not graded
NHNVF	Nonhip nonvertebral fracture
NVF	Nonvertebral fracture
ODT	Osteoporosis drug therapy
ONJ	Osteonecrosis of the jaw
PBO	Placebo
PICOTS	Population, intervention, comparison, outcome, timing, setting/study design
PM	Postmenopausal
RCT	Randomized controlled trial
RLX	Raloxifene
ROB	Risk of bias
RRR	Relative risk reduction
RVF	Radiographic vertebral fracture
Rx	Prescription
SAE	Serious adverse events
SOE	Strength of evidence
ST/FSF	Subtrochanteric/femoral shaft fracture
T	BMD T-score
TH	Total hip
VTE	Venous thromboembolic events
YR	Year
ZA	Zoledronic acid